scholarly journals Analysis on the Efficacy and Safety of the Patients with Advanced Ovarian Cancer

2015 ◽  
Author(s):  
Yunxia Xue ◽  
Xingyun Sun ◽  
Peijing Shi
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Efficacy And Safety

Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 5529-5529 ◽  
Author(s):  
Susan M. Domchek ◽  
Ronnie Shapira-Frommer ◽  
Rita K. Schmutzler ◽  
M. William Audeh ◽  
Michael Friedlander ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Advanced Ovarian Cancer ◽  
Efficacy And Safety ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Clinical efficacy and safety of apatinib combined with oral VP-16 for the treatment of advanced ovarian cancer: Preliminary evaluation of a clinical drug regimen

2020 ◽  
Vol 6 (2) ◽  
pp. 209-213
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Carcinoma ◽  
Clinical Efficacy ◽  
Advanced Ovarian Cancer ◽  
Symptomatic Treatment ◽  
Drug Regimen ◽  
Preliminary Evaluation ◽  
Efficacy And Safety ◽  
Advanced Ovarian Carcinoma ◽  
Hand Foot Syndrome

To investigate the clinical efficacy and safety of apatinib in combination with oral VP-16 for the treatment of chemotherapy-resistant advanced ovarian carcinoma. Twenty-seven advanced ovarian carcinoma patients were treated with oral VP-16 chemotherapy combined with oral apatinib mesylate (500 mg/d). CA125, VEGF, and CEA were examined every 3-4 weeks, and tumour changes were monitored by CT every 8-12 weeks. PFS was obtained by follow-up after discharge. For all patients, the ORR (including CR and PR) was 25.0%, and the DCR (including CR, PR and SD) was 75.0%. CEA and CA199 significantly decreased (p<0.05), but the decrease in VEGF was not significant. The average PFS was 5.13 months. The ECOG score had a significant effect on PFS (p<0.05), while there were no significant differences in PFS based on age (p=0.394). The main side effects of this regimen were hypertension, proteinuria, hand-foot syndrome and myelosuppression, which were tolerated by patients after active symptomatic treatment. Apatinib combined with oral VP-16 is an effective regimen for the treatment of chemotherapy-resistant advanced ovarian cancer. This combination therapy should be widely used in clinical practice.

scholarly journals 347 Efficacy and safety of niraparib in older patients (PTS) with advanced ovarian cancer (OC): results from the prima/ENGOT-OV26/GOG-3012 trial

2020 ◽  
Author(s):  
Hanna Dahlstrand ◽  
Bhavana Pothuri ◽  
Whitney Graybill ◽  
Thibault de La Motte Rouge ◽  
Colleen Mccormick ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Older Patients ◽  
Advanced Ovarian Cancer ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document